Key Features and Benefits
- Accurate: Detects 98 targets on SARS-CoV-2 RNA for highly accurate detection of
- Comprehensive: Reports consensus sequence when +90 amplicons are detected
- Quality Controlled: Built-in quality control in every reaction
- Flexible: Seamless end-to-end workflow; temperature specification allows use of
This amplicon-based next-generation sequencing (NGS) assay is designed to help clinical research
labs identify novel strains of SARS-CoV-2. It includes 2019-nCoV primers to detect mutations and
characterize RNA from the SARS-CoV-2 virus.
Rapid, Low-Throughput SARS-CoV-2 Detection
The Illumina COVIDSeq Assay accommodates a low number of samples. The workflow includes steps for viral RNA
extraction, RNA-to-cDNA conversion, PCR, library preparation, sequencing, analysis, and report generation.
Design and Quality Control
The assay leverages a modified version of the publicly available ARTIC multiplex PCR protocol, with 98
amplicons designed to amplify SARS-CoV-2 virus-specific sequences, combined with proven Illumina sequencing
technology. A 63°C annealing temperature at the PCR step improves variant analysis—providing important
insight into the SARS-CoV-2 strain present in the sample.
Upload consensus sequence information (FASTA file) into open software tools to assign lineage and annotate
mutations. For added convenience, upload files to the NCBI and/or GISAID App directly through BaseSpace
Questions about whether this assay is a good fit for your needs? Contact Us today.